Kancera AB engages in the research, development, and sale of drug candidates to pharmaceutical companies. It focuses on Fractalkine program which develops a candidate drugs for treatment of severe inflammatory diseases and cancer. The company was founded by Hakan Mellstedt on April 28, 2010 and is headquartered in Solna, Sweden.